Antitrust

CCI approves (a) acquisition of majority shareholding in Optimus Drugs Private Limited (ODPL) by Sekhmet Pharmaventures Private Limited (Sekhmet); and (b) ODPL’s acquisition of shareholding in Optimus Pharma Private Limited (OPPL) and Optimus Life Science Private Limited (OLSPL) under Section 31(1) of the Competition Act, 2002.

Date 12/08/2022
 
Press Release (339.55 KB)